Sarpogrelate, an antagonist of 5-HT2A receptor, treatment reduces restenosis after coronary stenting

被引：0
|
作者：
Fujita, M
Mizuno, K
Ho, M
Miwa, K
机构：
[1] Kyoto Univ, Coll Med Technol, Kyoto 606, Japan
[2] Nippon Med Coll, Chiba Hokusoh Hosp, Chiba, Japan
[3] Kawasaki Social Insurance Hosp, Kawasaki, Kanagawa, Japan
[4] Kansai Elect Power Hosp, Osaka, Japan
来源：
CIRCULATION | 2002年 / 106卷 / 19期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2927
引用
收藏
页码：592 / 592
页数：1
相关论文
共 50 条
  • [31] Protective effects of sarpogrelate, a 5-HT2A antagonist, against postischemic myocardial dysfunction in guinea-pig hearts
    Tatsuya Muto
    Yoshihiro Hotta
    Kunihiro Miyazeki
    Hiroaki Ando
    Naohisa Ishikawa
    Takaaki Hasegawa
    Yumi Sugimoto
    Jun Yamada
    Yasuyoshi Miki
    Molecular and Cellular Biochemistry, 2005, 272 : 119 - 132
  • [32] Protective effects of sarpogrelate, a 5-HT2A antagonist, against postischemic myocardial dysfunction in guinea-pig hearts
    Muto, T
    Hotta, Y
    Miyazeki, K
    Ando, H
    Ishikawa, N
    Hasegawa, T
    Sugimoto, Y
    Yamada, J
    Miki, Y
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2005, 272 (1-2) : 119 - 132
  • [33] Effect of 5-HT2A receptor antagonist ketanserin on micturition in male rats
    Wang Xiaohua
    Cao Nailong
    Ni Jianshu
    Si Jiemin
    Gu Baojun
    Karl-Erik, Andersson
    NEUROSCIENCE LETTERS, 2018, 687 : 196 - 201
  • [34] EMD 281014, a new selective serotonin 5-HT2A receptor antagonist
    Bartoszyk, GD
    van Amsterdam, C
    Böttcher, H
    Seyfried, CA
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2003, 473 (2-3) : 229 - 230
  • [35] Sarpogrelate Hydrochloride, a Selective 5-HT2A Receptor Antagonist, Improves Skin Perfusion Pressure of the Lower Extremities in Hemodialysis Patients with Peripheral Arterial Disease
    Hidaka, Sumi
    Kobayashi, Shuzo
    Iwagami, Masao
    Isshiki, Rei
    Tsutsumi, Daimu
    Mochida, Yasuhiro
    Ishioka, Kunihiro
    Oka, Machiko
    Maesato, Kyoko
    Moriya, Hidekazu
    Ohtake, Takayasu
    RENAL FAILURE, 2013, 35 (01) : 43 - 48
  • [36] Effects of a 5-HT2 receptor agonist (DOI) and a 5-HT2A receptor antagonist (ketanserin) on interval timing behaviour
    Body, S
    Kheramin, S
    Ho, MY
    Miranda, F
    Bradshaw, CM
    Szabadi, E
    JOURNAL OF PSYCHOPHARMACOLOGY, 2003, 17 (03) : A69 - A69
  • [37] 5-HT2A Receptor Signaling
    Panicker, M. M.
    JOURNAL OF NEUROCHEMISTRY, 2013, 125 : 25 - 25
  • [38] SEROTONIN 5-HT2A RECEPTOR ANTAGONISTS FOR TREATMENT OF SCHIZOPHRENIA
    Ebdrup, Bjorn H.
    Rasmussen, Hans
    Arnt, Jorn
    Glenthoj, Birte
    SCHIZOPHRENIA RESEARCH, 2012, 136 : S264 - S265
  • [39] 5-HT1B and 5-HT2A receptor antagonist properties of SL 65.0472 in vivo
    O'Connor, SE
    Grosset, A
    Duval, N
    La Rochelle, CD
    Gautier, E
    Bidouard, JP
    Janiak, P
    BRITISH JOURNAL OF PHARMACOLOGY, 2000, 129 : U36 - U36
  • [40] Role of 5-HT2A receptor antagonists in the treatment of insomnia
    Vanover, Kimberly E.
    Davis, Robert E.
    NATURE AND SCIENCE OF SLEEP, 2010, 2 : 139 - 150
12345